3 A Gold Rush Meets a Ticking Clock The radiopharmaceutical industry today resembles a 21st-century gold rush—venture capital pours into startups, Big Pharma inks multi-billion-dollar acquisitions, and every boardroom buzzes with talk of next-generation theranostics. Yet unlike conventional biologics, whose molecules remain stable for weeks or months, radioisotopes decay with predictable half-lives measured in hours […]